REST4-AAA Registry

Launched by RENJI HOSPITAL · Jun 29, 2025

Keywords

ClinConnect Summary

This clinical trial, called REST4-AAA Registry, is studying a condition known as abdominal aortic aneurysm (AAA), which is when a large blood vessel in the belly area (the aorta) becomes enlarged and can be at risk of bursting. The study aims to find out if a specific substance in the blood, called REST4, can help doctors measure the size of the aneurysm and predict how quickly it might grow or the chance it could rupture. REST4 is a protein that might increase when the aneurysm is developing, and researchers want to see if checking its levels could be a useful tool for managing this condition.

People who might join this study are adults aged 50 or older with an AAA that is between 39 and 49 millimeters wide, who are of Han nationality, and who do not have mental illness or certain other health problems like previous major aortic surgery or serious infections. Participants will have their blood tested for REST4 levels at the start and will be followed for up to five years to track changes in their aneurysm size and health outcomes. This study is not yet recruiting, and those who join will need to agree to regular check-ups and follow the study procedures. The goal is to better understand how to monitor AAA and potentially improve care for people with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Presence of an infrarenal AAA with a maximum diameter of 39-49 mm;
• • 2. Han nationality;
• • 3. Between 50 years or more, no gender limit;
• • 4. No mental illness;
• • 5. Subjects voluntarily participate in this study, sign an informed consent form, have good compliance, and cooperate with follow-up.
• Exclusion Criteria:
• • 1. Previous infrarenal aortic surgery;
• • 2. Planned major surgery;
• • 3. Known aortic dissection;
• • 4. Have received any other clinical trial treatment within 1 year;
• • 5. Systemic treatment with corticosteroids or other systemic immunomodulatory therapy;
• • 6. Severe infections, including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc.;
• • 7. Known or suspected inherited connective tissue disorder;
• • 8. Known or suspected prostate cancer;
• • 9. Calculated creatinine clearance of less than 30 ml/min;
• • 10. Known significant liver disease;
• • 11. Known human immunodeficiency virus infection at the time of screening；
• • 12. Serious concomitant illness associated with life expectancy of less than 2 years；
• • 13. Any other significant and unstable condition that could limit compliance with the trial protocol.